14 slides from Swedish Orphan Biovitrum Ab's shareholder meeting presentation, May 6, 2026
Slide 1: Annual General Meeting 2026 CEO presentation
Annual General Meeting 2026 CEO presentation 6 May, 2026 1
Slide 2: Forward-looking statements
Forward-looking statements In order to utilise the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum AB (publ) (Sobi®) is providing the following cautionary statement: This presentation contains forward-looking statements with re
Slide 3: Strategy and strategic objectives
Strategy and strategic objectives Rare diseases remain profoundly underdiagnosed and undertreated, and the need for meaningful innovation continues to grow. Level up At Sobi we continue to: • Strengthen therapeutic area leadership • Broaden the global footprint • Put patient-centered sustainability
Slide 4: Strong revenue performance fueling growth into 2026
Strong revenue performance fueling growth into 2026 FY 2025 revenue growth +15% at CER FY FY Total revenue (SEK M) (2024 in comparison) Amounts in SEK M 2025 2024 Change Specialty Care Immunology Haematology Total revenue 28,238 26,027 +8% 7,776 7,821 +9% 7,436 Gross profit 21,986 20,242 347 341 6,8
Slide 5: Growth delivered by strong momentum across the business and across all regions
Growth delivered by strong momentum across the business and across all regions Total net sales, SEK M, growth at CER Revenue by Therapeutic area Revenue by region Strategic1 +15% Foundational Europe 10,815 20% 28,238 4% 26,027 28% North 16,698 America 9,313 +19% 12,346 (59%) (47%) 68% International
Slide 6: Continuing to build and strengthen our Global footprint to increase access and impact
Continuing to build and strengthen our Global footprint to increase access and impact Sobi revenues1, SEK bn Sobi territories2 – coverage of > 90% of Global Mkt.3 US +11% >100 Launches across Sobi 9.3 territories 5.5 in last 5 years 2020 2025 Europe +7% 9 new 10.8 7.6 organisations since 2020, 2020
Slide 7: 2025: A year of progress and purpose
2025: A year of progress and purpose >53,000 Gamifant approval in US full-time equivalent Approved for HLH/MAS in patients were treated individuals with Still’s disease. with a Sobi medicine This is the first approved treatment for those affected by these severe, potentially life- threatening hyperi
Slide 8: Acquisition of Arthrosi Therapeutics: establishing Sobi as a leader in gout
Acquisition of Arthrosi Therapeutics: establishing Sobi as a leader in gout Unlock a major commercial opportunity – more than Gout portfolio 200,000 patients with uncontrolled gout in the US alone Complementing our registrational asset NASP for severe uncontrolled gout and scaling in an area of Laun
Slide 9: Q1 2026: Strong growth of 24% at CER delivered by our portfolio and across all regions
Q1 2026: Strong growth of 24% at CER delivered by our portfolio and across all regions Total net sales, SEK M, growth at CER Strategic products, SEK M Revenue by region Doptelet 1 433 Strategic1 +24% Foundational Europe 2,866 +20% 7,184 Altuvoct 1 240 6,465 Gamifant 734 Aspaveli / North 371 2,379 +2
Slide 10: Building on progress: Launches and pipeline delivery in 2026
Building on progress: Launches and pipeline delivery in 2026 Launch excellence Pipeline execution Altuvoct launch continues Tryngolza sHTG pre-launch activities in all major countries Pozdeutinurad – progressive gout Phase 3 program data readout Initial launch of Aspaveli in Europe NASP – uncontroll
Slide 11: Looking ahead: Sobi is entering a unique moment of opportunity
Looking ahead: Sobi is entering a unique moment of opportunity, with 6 big launches and 5 potential blockbusters Timeline 2024 2025 2026 2027 2028 2029 2030 Haemophilia A HLH / MAS C3G / IC-MPGN Uncontrolled gout NASP sHTG Progressive gout pozdeutinurad Joint Health / Synovitis1 VEXAS2 5 assets with
Slide 12: Setting a new ambition: Doubling Sobi to SEK 55bn by 2030
With such opportunities we are setting a new ambition: Doubling Sobi to SEK1 55bn by 2030 Revenue, in SEK bn ILLUSTRATIVE ONLY, NOT TO SCALE 6 major launches 55 Altuvoct in HA Gamifant HLH/MAS Priority Portfolio development renewal programmes through NASP in BD uncontrolled gout Gamifant in IDS Stra
Slide 13: Sustainability drives our strategic business priorities and decisions
Sustainability drives our strategic business priorities and decisions Managing carbon footprint1 – Patient Responsible in context of strong growth commitment behaviour CO2e in kt Revenues in SEK B ▪ Access to treatment ▪ Safe and healthy work 2.0 28.2 30 ▪ Patient centricity and 1.9 ▪ A fair and inc
Slide 14: Sobi delivered clear value in 2025 and represents a compelling investment opportunity
+15% We want to double Sobi to SEK 55bn revenue by revenue at CER in 2025 40% 1 2030, with sustained growth beyond EBITA margin adjusted After a period of investment, we expect adjusted 2 EBITA margins to return to the upper-30% range Sobi delivered clear value in 2025 and represents a compelling We